open access
Relationship between thyroid hormone levels in euthyroid patients before HSCT and time to achieve neutrophil and platelet engraftment: an analytical cross-sectional study
Affiliations- Internal Medicine Specialist, Tabriz University of Medical Science, Tabriz, Iran, Islamic Republic Of
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic Of
- Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic Of
open access
Abstract
Introduction. The time to reach neutrophil (NE) and platelet engraftment (PE) in hematopoietic stem cell transplantation (HSCT) is one of the most important factors indicating transplantation survival. The aim of this study was to investigate the relationship between thyroid hormone levels before HSCT and the time to achieve NE and PE. Material and methods. The relationship between thyroid hormone levels before HSCT, age, gender, type of HSCT, type of disease and cluster of differentiation 34+ (CD34+) cell count and the number of days to reach NE and PE was examined in 37 clinically and laboratorially euthyroid patients. Results. An odds ratio (OR) of > 6 was observed in the probability of time to NE > 10 days in patients with thyroid-stimulating hormone (TSH) > 2.89 mU/L in the upper normal range (UNR) and male patients, also in the probability of time to PE > 15 days in patients with TSH > 2.89 mU/L in the UNR. Statistically significant p-value and confidence interval were found in the probability of time to NE > 10 days in male patients (OR = 8.58, p-value = 0.036) and time to PE > 15 days in patients with TSH > 2.89 mU/L in the UNR (OR = 14.32, p-value = 0.041). Conclusions. Treatment with low dose levothyroxine can be cautiously recommended to achieve TSH to ≤2.8 mU/L in the lower normal range before performing HSCT in euthyroid patients, which will reduce the times to NE and PE and help earlier discharge of patients.
Abstract
Introduction. The time to reach neutrophil (NE) and platelet engraftment (PE) in hematopoietic stem cell transplantation (HSCT) is one of the most important factors indicating transplantation survival. The aim of this study was to investigate the relationship between thyroid hormone levels before HSCT and the time to achieve NE and PE. Material and methods. The relationship between thyroid hormone levels before HSCT, age, gender, type of HSCT, type of disease and cluster of differentiation 34+ (CD34+) cell count and the number of days to reach NE and PE was examined in 37 clinically and laboratorially euthyroid patients. Results. An odds ratio (OR) of > 6 was observed in the probability of time to NE > 10 days in patients with thyroid-stimulating hormone (TSH) > 2.89 mU/L in the upper normal range (UNR) and male patients, also in the probability of time to PE > 15 days in patients with TSH > 2.89 mU/L in the UNR. Statistically significant p-value and confidence interval were found in the probability of time to NE > 10 days in male patients (OR = 8.58, p-value = 0.036) and time to PE > 15 days in patients with TSH > 2.89 mU/L in the UNR (OR = 14.32, p-value = 0.041). Conclusions. Treatment with low dose levothyroxine can be cautiously recommended to achieve TSH to ≤2.8 mU/L in the lower normal range before performing HSCT in euthyroid patients, which will reduce the times to NE and PE and help earlier discharge of patients.
Keywords
neutrophil engraftment, platelet engraftment, HSCT, thyroid function, TSH, free T4
Supp./Additional Files (4)
About this articleTitle
Relationship between thyroid hormone levels in euthyroid patients before HSCT and time to achieve neutrophil and platelet engraftment: an analytical cross-sectional study
Journal
Issue
Article type
Original research article
Pages
398-406
Published online
2022-11-02
Page views
1092
Article views/downloads
87
DOI
10.5603/AHP.a2022.2051
Bibliographic record
Acta Haematol Pol 2022;53(6):398-406.
Keywords
neutrophil engraftment
platelet engraftment
HSCT
thyroid function
TSH
free T4
Authors
Sepideh Tahsini Tekantapeh
Nasrin Gholami
Roya Dolatkhah
Vahideh Sadra
Mehdi Derakhshani
Babak Nejati
Ali Akbar Movassaghpour
References (28)- Randolph B, Ciurea S. What the intensivist needs to know about hematopoietic stem cell transplantation? Oncologic Critical Care. 2019: 1531–1546.
- Passweg JR, Halter J, Bucher C, et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly. 2012; 142: w13696.
- Hutt D. Chapter 13. Engraftment, graft failure, and rejection. In: Kenyon M, Babic A. ed. The European blood and marrow transplantation textbook for nurses. Springer, Cham 2018: 259–270.
- Servais S, Beguin Y, Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Emerg Drugs. 2013; 18(2): 173–192.
- Yanir AD, Hanson IC, Shearer WT, et al. High incidence of autoimmune disease after hematopoietic stem cell transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018; 24(8): 1643–1650.
- Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002; 29(7): 545–552.
- Teltschik HM, Heinzelmann F, Gruhn B, et al. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016; 175(1): 115–122.
- Ali MY, Oyama Y, Monreal J, et al. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant. 2002; 30(11): 749–752.
- Rihn C, Cilley J, Naik P, et al. Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004; 89(6): 763–764.
- Ruggeri A, Labopin M, Sormani MP, et al. Eurocord, Cord Blood Committee EBMT, Netcord. Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. Haematologica. 2014; 99(9): 1509–1515.
- Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) . Blood. 2000; 95(12): 3702–3709.
- Schmitz N, Beksac M, Hasenclever D, et al. European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002; 100(3): 761–767.
- Matthews J, Matheny L, Jagasia S. Thyroid disease: monitoring and management guidelines. Blood and Marrow Transplantation Long Term Management. 2021: 183–188.
- Au WY, Lie AKW, Kung AWC, et al. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 35(4): 383–388.
- Younes E, Hussein A, Al-zaben A, et al. Incidence and predicting factors of abnormal thyroid function test in adult patients post haematopoietic stem cell transplantation at King Hussein cancer centre: P931. Bone Marrow Transplant. 2012; 47.
- Sağ E, Gönç N, Alikaşifoğlu A, et al. Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a report of four cases. J Clin Res Pediatr Endocrinol. 2015; 7(4): 349–354.
- Mazzolari E, Forino C, Guerci S, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol. 2007; 120(4): 892–899.
- Vantyghem MC, Cornillon J, Decanter C, et al. Société Française de Thérapie Cellulaire. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis. 2014; 9: 162.
- Siekierska-Hellmann M, Babińska A, Obołończyk L, et al. [One-year follow-up of TSH level and thyroid volume in patients with bone marrow or peripheral blood hematopoietic stem cell transplantation following chemotherapy]. Pol Merkuriusz Lek. 2007; 23(135): 170–173.
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3): 756–763.
- Buxbaum NP, Pavletic SZ. Autoimmunity following allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020; 11: 2017.
- Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000; 96(13): 4096–4102.
- Tabbara IA, Zimmerman K, Morgan C, et al. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002; 162(14): 1558–1566.
- Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood. 2009; 113(2): 306–308.
- Medinger M, Zeiter D, Heim D, et al. Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Leuk Res. 2017; 58: 43–47.
- Li Z, Rubinstein SM, Thota R, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22(8): 1368–1375.
- Holbro A, Abinun M, Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol. 2012; 157(3): 281–290.
- Milenković T, Vujić D, Vuković R, et al. Subclinical hypothyroidism in children and adolescents after hematopoietic stem cells transplantation without irradiation. Vojnosanit Pregl. 2014; 71(12): 1123–1127.